HNGEHealthcare · Health Information ServicesThe 16 Wall Street analysts covering Hinge Health, Inc. hold a median 12-month price target of $90 — +15.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Hinge Health, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (99): Analysts have, on balance, been raising their forecasts.
Volatility (17): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Hinge Health, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on HNGE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +15.9% from it.
Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 July 2026 | Citizens | Maintains | Market Outperform | $80 → $96 |
| 27 July 2026 | Stifel | Maintains | Buy | $79 → $90 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | $76 → $100 |
| 21 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 13 July 2026 | Barclays | Maintains | Overweight | — |
| 13 July 2026 | Barclays | Maintains | Overweight | $70 → $97 |
| 13 July 2026 | Keybanc | Maintains | Overweight | $90 → $125 |
| 13 July 2026 | Keybanc | Maintains | Overweight | — |
| 13 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 13 July 2026 | Morgan Stanley | Maintains | Overweight | $72 → $108 |
| 24 June 2026 | Wells Fargo | Maintains | Overweight | $80 → $90 |
| 24 June 2026 | Wells Fargo | Maintains | Overweight | — |
| 17 June 2026 | Baird | Maintains | Neutral | $55 → $65 |
| 17 June 2026 | Baird | Maintains | Neutral | — |
| 15 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 15 June 2026 | Raymond James | Maintains | Outperform | — |
| 12 June 2026 | Keybanc | Maintains | Overweight | — |
| 11 June 2026 | Barclays | Maintains | Overweight | — |
| 11 June 2026 | Needham | Maintains | Buy | — |
| 11 June 2026 | RBC Capital | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 26% of US stocks
Cheaper than 15% of US stocks
Cheaper than 2% of US stocks
Cheaper than 85% of US stocks
Higher than 86% of US stocks
Higher than 87% of US stocks
Higher than 94% of US stocks
Higher than 77% of US stocks
Higher than 7% of US stocks
Higher than 10% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HNGE appears on the weeks it earns a place.
The article notes that stocks, including Eli Lilly, Twilio, and Hinge Health, are approaching earnings reports and advises investors to pay attention to key chart lines as that time nears.
Why it matters — A Hinge Health watcher would care because the piece highlights that HNGE's chart patterns are worth monitoring ahead of its upcoming earnings report.
A study published in the Journal of Comparative Effectiveness Research found that adults aged 65+ using Hinge Health reported 37% fewer falls and 57% lower odds of an emergency room visit at three months compared to a control group. Hinge Health announced the findings in a press release.
Why it matters — The study provides clinical evidence that Hinge Health's offering reduces fall risk and ER visits for older adults, a key demographic for the company's growth.
Zacks Investment Research reports that Hinge Health (HNGE) lacks the key combination needed for a likely earnings beat in its upcoming report.
Why it matters — This assessment may influence investor expectations about HNGE's near-term financial performance ahead of its earnings release.
The 16 Wall Street analysts covering Hinge Health, Inc. have a median 12-month price target of $90, with estimates ranging from $65 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Hinge Health, Inc., 15 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Hinge Health, Inc. 70 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Hinge Health, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (99 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +15.9% from the last close, and Ticker Nerd's factor model ranks Hinge Health, Inc. 70 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Hinge Health, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HNGE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $125 over the next 12 months.
Hinge Health, Inc. returned +72.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Hinge Health Inc. is a digital health company specializing in software and wearable technology designed to improve joint and muscle health.
The most recent item we track (Investors Business Daily, 3 Aug 2026): "Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test". The article notes that stocks, including Eli Lilly, Twilio, and Hinge Health, are approaching earnings reports and advises investors to pay attention to key chart lines as that time nears.
Hinge Health Inc. is a digital health company specializing in software and wearable technology designed to improve joint and muscle health. The company's primary platform delivers digital exercise therapy programs, enabling users to proactively manage musculoskeletal conditions, acute injuries, chronic pain, and post-surgical rehabilitation. By integrating digital care pathways and connected devices, Hinge Health empowers patients to access evidence-based therapy remotely, reducing barriers associated with traditional in-person care. Founded in 2012 and headquartered in San Francisco, Hinge Health serves a diverse client base, including employers and health plans, seeking to lower healthcare costs and improve outcomes for members with musculoskeletal needs. The company’s solutions span clinical support, personalized exercise regimens, and tracking tools, providing a comprehensive approach to care. With strong revenue growth and a focus on innovation in digital therapeutics, Hinge Health plays a significant role in the evolving landscape of healthcare technology and value-based care models.
CEO Mr. Daniel A. Perez · 1,437 employees · United States · https://www.hingehealth.com